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Peter H. Howarth, MD, DM,a,b Donna E. Davies, PhD,a,b and Jane E. Collins, PhDa,b Southampton and Slough, United KingdomBackground: Because TNF-a is increased in severe asthma, we
hypothesized that TNF-a contributes to barrier dysfunction and
cell activation in bronchial epithelial cells. We further
hypothesized that src-family kinase inhibition would improve
barrier function in healthy cells in the presence of TNF-a and
directly in cultures of severe asthmatic cells where the barrier is
disrupted.
Objectives: We assessed the effect of TNF-a, with or without
src-family kinase inhibitor SU6656, on barrier properties and
cytokine release in differentiated human bronchial epithelial
cultures. Further, we tested the effect of SU6656 on
differentiated primary cultures from severe asthma.
Methods: Barrier properties of differentiated human bronchial
epithelial air-liquid interface cultures from healthy subjects and
subjects with severe asthma were assessed with transepithelial
electrical resistance and fluorescent dextran passage. Proteins
were detected by immunostaining or Western blot analysis and
cytokines by immunoassay. Mechanisms were investigated with
src kinase and other inhibitors.
Results: TNF-a lowered transepithelial electrical resistance and
increased fluorescent dextran permeability, caused loss of
occludin and claudins from tight junctions with redistribution of
p120 catenin and E-cadherin from adherens junctions, and also
increased endogenous TNF-a, IL-6, IL-1b, IL-8, thymic stromal
lymphoprotein, and pro–matrix metalloprotease 9 release.
SU6656 reduced TNF-a–mediated paracellular permeability
changes, restored occludin, p120, and E-cadherin and lowered
autocrine TNF-a release. Importantly, SU6656 improved the
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Open access under CC BY license.cultures. Redistribution of E-cadherin and p120 was observed in
bronchial biopsies from severe asthmatic airways.
Conclusions: Inhibiting TNF-a or src kinases may be a
therapeutic option to normalize barrier integrity and cytokine
release in airway diseases associated with barrier dysfunction.
(J Allergy Clin Immunol 2013;132:665-75.)
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The pulmonary airway epithelium resides at a critical external
interface, exposed to harmful aerosols and pathogens. The
proximal bronchial epithelium comprises columnar-ciliated cells
and mucus-secreting goblet cells supported by basal cells, to
generate a selective permeability barrier to control fluid loss,
entry of pathogens, and inappropriate immune reactions in the
subepithelial lung mucosa.1 In surface epithelial cells, tight junc-
tions (TJs) encircle the subapical regions of lateral cell mem-
branes to regulate permeability via the paracellular pathway
and to restrict lateral movement in the cell membrane, while inter-
cellularly connecting to the actin cytoskeleton.2 The physical bar-
rier function of TJs relies on the expression and interaction
of protein complexes, including integral membrane proteins,
claudins, occludin, tricellulins, Marvel D and junctional adhesion
molecules, cytoskeletal linker proteins, zonula occluden (ZO)-1,
ZO-2, and ZO-3, cingulin and 7H6, and associated signaling and
cell cycle regulators that control junction assembly, proliferation,
and differentiation.3-7 The TJ barrier appears to discriminate on
the basis of size and charge2 encompassing a leak pathway for
large solutes and a pore pathway (approximately 4A) of variable
pore density for small uncharged molecules and ions. Further se-
lectivity of paracellular ion permeability is contributed by the ap-
proximate 27-member claudin family of variably coexpressed
proteins.8,9 Occludin has been shown to be important in
cytokine-mediated barrier responses, and perturbations in occlu-
din result in independent modification of ion and macromolecular
permeability.10,11
Below the TJ is the actin-linked zonula adherens junction
(AJ),12,13 whereas keratin-linked desmosomes provide additional
cohesion.14 TheAJ, comprising E-cadherin and catenins, is impli-
cated in assembly and maintenance of TJs.15 E-cadherin and
ZO-1 associate with catenins in the initial stages of de novo junc-
tion assembly before formation of mature tight and AJs.16 Pertur-
bation experiments have shown that E-cadherin is important for
TJ assembly in Madin-Darby canine kidney epithelial (MDCK)
cells15 and transformed human bronchial epithelial (16HBE)
cells17; therefore, its regulation must be considered in the context
of barrier control in the airway.18,19665
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of TJs and increased permeability, especially in severe dis-
ease.1,20 TNF-a is increased in airways of severe, corticosteroid
refractory patients with asthma and implicated in airway pathol-
ogy,21,22 whereas in healthy subjects inhalation of TNF-a trig-
gers airway constriction, hyperresponsiveness, and sputum
neutrophilia.23 TNF-a promotes epithelial barrier dysfunction
in other tissues,2 and previous studies reported that TNF-a in
conjunction with IFN-g caused TJ disruption in cultured bron-
chial epithelia.24,25 However, information is scarce on the spe-
cific effects of TNF-a on claudins, barrier changes, and
epithelial-specific cytokine release. Modeling airway inflamma-
tion with bronchial epithelial air-interface cultures challenged
with TNF-a, we hypothesized that TNF-a disrupts TJs of human
airway epithelium and promotes inflammatory cytokine release.
We also investigated mechanisms that control these responses
and found that Src family kinases and modifications to E-cad-
herin and p120 catenin were involved. We confirmed that
p120 is disrupted in severe asthma and that SU6656 improves
barrier function in air-liquid interface (ALI) cultures from do-
nors with severe asthma. Our data suggest that barrier disruption
may be amenable to pharmacologic intervention in severe asth-
matic disease. Parts of this work were published in abstract
form.26METHODS
For additional information on the assessments, analyses, andmeasurements
used, please see the Methods section in this article’s Online Repository at
www.jacionline.org.Clinical characterization of subjects and
bronchoscopy
Following ethical approval and informed consent, subjects underwent fiber
optic bronchoscopy under local anesthesia for collection of bronchial biopsies
and brushings.27 All volunteers were nonsmokers and were free from respira-
tory tract infections for at least 4 weeks before the study. Further clinical in-
formation is included in Table E1 (in the Online Repository available at
www.jacionline.org).Culture and differentiation of primary bronchial
epithelial cells
Human bronchial epithelial cell (HBEC) cultures were grown from
bronchial brushings28 and differentiated for 21 days at anALI.20Differentiated
cultures were treated basolaterally with TNF-a (10 ng/mL) or other agents as
detailed in the Results section.
Measurement of TER and assessment of epithelial
barrier integrity
The transepithelial electrical resistance (TER) was measured with an
epithelial volt ohm meter (EVOM) with STX2 electrode (World Precision
Instruments, Aston, United Kingdom). Fluorescein isothiocyanate (FITC)-dex-
tran 4 kDa (Sigma-Aldrich, Poole,UnitedKingdom)was applied to cells apically
and incubated for 3 hours at 378C.Basolateral dextran passagewas analyzedwith
a Fluoroskan Ascent FL2.5 reader (Thermo Fisher, London, United Kingdom).
Exogenous cytokines, small molecule inhibitors,
and neutralizing antibodies
TNF-a (R&D Systems Europe Ltd, Abingdon, United Kingdom) was
reconstituted in PBS-0.1% BSA; SU665629 (Sigma-Aldrich), matrix metallo-
protease 9 (MMP-9) inhibitor 1 (Merck, London, United Kingdom), and
GM6001 (Millipore, Nottingham, United Kingdom) were reconstituted in di-
methyl sulfoxide and diluted for use; vehicle controls were routinely included.
Cells were preincubated with inhibitors for 2 hours before adding TNF-a.
Immunocytochemistry
Junctional proteins were detected in ALI cultures by immunofluorescent
staining with the use of mouse monoclonal antibodies (mAbs) against p120
catenin (BD Biosciences, Oxford, United Kingdom), claudin-3, claudin-4,
occludin, and E-cadherin and rabbit anti–claudin-8 (all Invitrogen, Paisley,
United Kingdom) with the nuclear counterstain, 7-amino-actinomycin D
(Sigma-Aldrich). Staining was assessed with a confocal Leica SP5 micro-
scope with the use of identical settings between conditions.
Immunohistochemistry
Bronchial biopsies were acetone-fixed and embedded in glycolmethacry-
late resin. Sections (2 mm) were immunostained with mAbs against
E-cadherin (Invitrogen), p120 catenin (BD Biosciences), and neutrophil
elastase (clone NP57; Dako, Cambridgeshire, United Kingdom) with the
use of standard protocols.30 In all cases, analyses were restricted to areas of
well-orientated and structurally intact epithelium.
Western blot analysis
Cell lysates were subjected to SDS-PAGE and Western blot analysis with
the use of anti-p120 catenin (Y228 and Y280), anti–total p120 catenin (BD
Biosciences), and anti–b-actin with horseradish peroxidase–electrochemilu-
minescence (HRP-ECL) detection (Amersham Biosciences, London, United
Kingdom).
RT-qPCR for TNF-a
Samples were processed with RNeasy kit (Qiagen, Manchester, United
Kingdom) for total RNA before cDNA synthesis. Primers for TNF-a with
ubiquitin C and glyceraldehyde 3-phosphate dehydrogenase housekeeping
genes (PrimerDesign, Southampton, United Kingdom) were used to quantify
expression with the use of a TaqMan 7900HT machine (Applied Biosystems,
Foster City, Calif) and analyzed with the DDCt method.
MSD multiplex cytokine array and ELISA assays
Conditioned media were assayed for IL-1b, IL-6, IL-8, TNF-a, IL-10, and
MMP-9with the use of an electrochemiluminescence immunoassay according
to the manufacturer’s protocol (Meso Scale Discovery [MSD], Rockville,
Md). Conditioned media were assayed for thymic stromal lymphoprotein
FIG 1. Effect of TNF-a on HBEC barrier function and TJ staining. A, Day 4 TER (n5 9). B, Day 4 FITC-dextran
permeability (n 5 8). Representative immunofluorescent photomicrographs (n 5 8) are controls (C, E, G,
and I) or TNF-a (D, F, H, and J) for occludin (C and D), claudin-3 (E and F), claudin-4 (G and H), and
claudin-8 (I and J) with TJ staining green and nucleii stained red. XZ stacks are labeled apical and basolat-
eral. Scale bar, 50 mm.Ap, Apical; Baso, basolateral; cl3, claudin-3; cl4, claudin-4; cl8, claudin-8; con, control;
occl, occludin; TNF, TNF-a.
FIG 2. TNF-a caused an increase in innate immune cytokine release from primary differentiated HBECs.
Basolateral medium taken every 24 hours from cells treated with TNF-awas assayed for cytokines and TNF
mRNA. TNF-a caused significant increases in TNF-amRNA (D) (n5 3) and release of endogenous TNF-a (A),
IL-1b (B), IL-6 (C), IL-8 (E) (all n 5 7), and TSLP (F) (n 5 5).
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use of an ELISA according to the manufacturer’s protocol (R&D Systems
Europe Ltd).LDH assay for cytotoxicity
Conditioned media were assayed for lactate dehydrogenase (LDH), using the
manufacturer’s protocol (RocheDiagnosticsLtd,BurgessHill,UnitedKingdom).
FIG 3. SU6656 inhibited TNF-a–mediated changes in macromolecular barrier function and TJ staining.
Effect of TNF-a without (light gray bars) or with (dark gray bars) SU6656 on TER (A) (n 5 8) or the
FITC-dextran permeability (B) (n 5 8); data are expressed relative to controls without or with SU6656. Rep-
resentative immunofluorescent photomicrographs (n 5 8) are control (C and G), TNF-a (D and H), SU6656
alone (E and I), or SU6656/TNF-a (F and J) for claudin-4 (C-F) or occludin (G-J). XZ stacks are labeled apical
and basolateral. Scale bar, 50 mm. Ap, Apical; Baso, basolateral; cl4, claudin-4; con, control; occl, occludin;
SU, SU6656; TNF, TNF-a.
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Data were evaluated with nonparametric Wilcoxon rank sum or 2-way
ANOVA test. All the data were analyzed with Prism (GraphPad Software,
La Jolla, Calif).RESULTS
TNF-a caused an increase in ion and
macromolecular barrier permeability
Differentiated healthy bronchial epithelial ALI cultures,
treated for 4 days basolaterally with 10 ng/mL TNF-a, showed
a significant 3- to 4-fold decrease in TER (Fig 1, A) and a sig-
nificant 6- to 7-fold increase in macromolecular permeability to
FITC-labeled 4-kDa dextran (Fig 1, B) compared with controls.
Concentration- and time-dependent changes in TER (see
Fig E1, A and B, in this article’s Online Repository at www.
jacionline.org) and FITC dextran permeability (see Fig E1, C
and D) were observed. LDH assays showed no cellular toxicity
(see Fig E1, E).TNF-a–mediated decrease in barrier permeability
correlated with loss of cell junction staining
Immunofluorescent staining of control ALI cultures for
occludin and claudin-3, -4, and -8 showed circumferential
staining characteristic of zonular epithelial cell junctions, with
a focused subapical location (Fig 1, C, E, G, and I). Occludin
staining was highly concentrated in TJ zones but was substan-
tially reduced with TNF-a, many cells appearing to have nostaining (Fig 1, D). Claudin-3, -4, and -8 were localized in a
zonular TJ pattern, although claudin-3 and -4 were less discrete
than claudin-8, with more lateral membrane staining (Fig 1, E,
G, and I). TNF-a caused loss and interruption in claudin-3 stain-
ing at plasma membrane and TJ areas with variable amounts of
cytosolic staining (Fig 1, F), whereas a loss of expression of
claudin-4 and -8 was observed, with redistribution of staining
from junction regions to basolateral areas of columnar cells
(Fig 1, H and J). Western blot analyses showed variable changes
in occludin and claudin-3, -4 and -8 in response to TNF-a, which
were not significantly different from controls, suggesting redistri-
bution of these proteins was the main effect (see Fig E2 in this
article’s Online Repository at www.jacionline.org).TNF-a stimulated release of TNF-a, IL-1b, IL-6,
IL-8, and TSLP but not IL-10
To assess the ability of TNF-a to stimulate cytokine release,
cell-conditioned medium was assayed for TNF-a, IL-1b, IL-6,
IL-8, TSLP, IL-33, and IL-10. After correction for exogenously
added TNF-a, a significant increase was observed in TNF-a
release at day 1, compared with controls, with a further increase
between day 1 and 2, which was maintained through day 4,
suggesting that the cells were releasing endogenous TNF-a
(Fig 2, A). This was supported by the observation that mRNA
for TNF-a was significantly increased at 24 and 72 hours
(Fig 2, D). IL-1b significantly increased 4- to 5-fold, IL-6 in-
creased significantly approximately 8-fold, and IL-8 release
showed a significant 4-fold increase. These increases occurred
FIG 4. The SFK inhibitor SU6656 inhibited TNF-a–mediated changes in E-cadherin and p120-catenin
staining and reduced endogenous TNF-a release. Representative immunofluorescent photomicrographs
(n 5 3) are control (A and E), TNF-a (B and F), SU6656 alone (C and G), or SU6656/TNF-a (D and H) for
E-cadherin (A-D) or p120 catenin (E-H). XZ stacks are labeled apical and basolateral. Bar 50 mm. I, shows
basolateral concentration of endogenous TNF-a without or with SU6656 (n 5 5). Ap, Apical; Baso, basolat-
eral; con, control; E-cad, E-cadherin; p120, p120 catenin; SU, SU6656 alone; TNFSU, SU6656/TNF-a; TNF,
TNF-a.
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treatment (Fig 2, B, C and E). TSLP was just above the limit
of detection in control cultures and increased by 25- to 100-
fold at day 1 of treatment, dropping back to approximately
10- to 50-fold by days 3 and 4 (Fig 2, F). IL-10 and IL-33 levels
were low (approximately 5 pg/mL) and not affected by TNF-a
(see Fig E3 in this article’s Online Repository at www.
jacionline.org). Although both IL-6 and IL-1b have been impli-
cated in epithelial barrier disruption, neutralizing antibodies to
either cytokine failed to prevent the TNF-a–mediated epithelial
barrier disruption (data not shown).TNF-a promoted an increase in proMMP-9 release
Because TNF-a has been shown to induce MMP-9 synthe-
sis,31 which could underlie the barrier disrupting effects of
TNF-a, MMPs were assessed in cell supernatant fluids.
ProMMP-9 was clearly detected in basolateral supernatant
fluids from TNF-a–treated cultures with the use of gelatin
zymography and ELISA (see Fig E4, A and B, in this article’s
Online Repository at www.jacionline.org). Further assessment
of MMP-9 activity with the use of a DQ collagen type IV con-
firmed that most MMP-9 was in the proform (see Fig E4, C),
suggesting that airway epithelial cells express proMMP-9 but
do not activate it in response to TNF-a alone. TIMP-1, a natural
inhibitor of MMP-9, was found to be reduced throughout the
4-day experiment; however, this occurred in both controls and
TNF-a–treated cultures (see Fig E4, D). To test the possibility
that MMP-9 was activated locally at its site of action, abroad-spectrum inhibitor of MMP-9 activity, GM6001 (100
nmol/L, 1 mmol/L, and 10 mmol/L) or the specific MMP-9 in-
hibitor 1 (10 mmol/L) were applied basolaterally or apically
during TNF-a treatment. However, these inhibitors did not at-
tenuate epithelial barrier disruption by TNF-a (data not shown),
suggesting that local activation of MMP-9 was not responsible
for disruption of TJ proteins.SFK inhibitor SU6656 reduced the effect of TNF-a
on macromolecular barrier permeability and
changes in TJ proteins
TNF-a has been shown to activate c-src kinase in airway
epithelial cells.32 Therefore, SU6656, an inhibitor of src family
kinases (SFKs),29 was tested for its ability to inhibit barrier
disruption in response to TNF-a. SU6656 (4 mmol/L) had no
significant effect on the resting TER (median [range], 1633
ohm/cm2 [1239-2507 ohm.cm2] vs 1718 ohm.cm2 [1375-2337
ohm.cm2]; P 5 .13) or basal permeability to FITC dextran (me-
dian [range], 0.26 [0.11-0.67] vs 0.28 [0.08-0.72]; P 5 .58) nor
did it significantly reverse the decrease in TER caused by
TNF-a (Fig 3, A; see also E5, A, in this article’s Online Repos-
itory at www.jacionline.org). In contrast, the effect of TNF-a
on permeability to uncharged sugars was clearly attenuated
by SU6656 with significant barrier improvement (Fig 3, B). Im-
munofluorescent staining showed that, although SU6656 was
unable to restore immunostaining of claudin-4 to control levels
(Fig 3, C-F), it prevented the TNF-a–mediated loss of occludin
from TJs (Fig 3, G-J, arrows), which was consistent with the
FIG 5. The effect of TNF-a and SU6656 on p120-catenin phosphorylation at
residues Y228 and Y280. A, Representative Western blot analysis of p120-
PY228, p120-PY280, total p120-catenin, and b-actin control. Shown are
lysates from control cells and cells treated with TNF-a, SU6656, or
SU6656/TNF-a. B, Ratio of signal intensities of p120-PY228 and total
p120-catenin after normalization to b-actin. TNF-a–mediated increase in
p120-PY228 was significantly reduced with SU6656 (n 5 3). C, Control;
T, TNF-a; S, SU6656; ST, SU6656/TNF-a.
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permeabilities.SU6656 inhibited the TNF-a–mediated loss of
junctional staining of E-cadherin and p120 catenin
and endogenous TNF-a release
TheTJ and closely apposed zonulaAJ depend on the stability of
E-cadherin, which is influenced by p120 catenin binding.33 Be-
cause SFKs are important for p120 catenin regulation,34-36 we as-
sessed E-cadherin and p120 catenin distribution in response to
TNF-a with SU6656. In control cells, immunostaining for
E-cadherin and p120 catenin showed a similar plasma membrane
distribution (Fig 4,A andE). AlthoughTNF-a treatment promoted
loss of immunostaining for E-cadherin (Fig 4, B), this was pre-
vented by treatment with SU6656 (Fig 4, D). Immunostaining
for p120 catenin became much brighter in response to TNF-a,
with an apparent increase in staining thickness along the plasma
membranes andmarked cytosolic staining (Fig 4,F). SU6656 pre-
vented this redistribution of p120 catenin immunostaining whichremained focused at the junctional membrane with much less cy-
toplasmic staining than with TNF-a alone (Fig 4, H), although
there was still some cytoplasmic staining compared with control
(Fig 4, E). SU6656 was also tested for effects on epithelial
TNF-a–mediated cytokine expression. It caused significant re-
duction of endogenous TNF-a release at 1, 3, and 4 days, with a
downward trend at day 2 (Fig 4, I). IL-6 showed a trend downward,
whereas release of IL-8, IL-1b (see Fig E5, B-D), or TSLP (data
not shown) was not significantly altered by SU6656.TNF-a treatment induced tyrosine phosphorylation
of p120-catenin which was attenuated by SU6656
The tyrosine residues within p120 catenin that are targets
of purified src kinase include p120-Y228 and p120-Y280.34
Consistent with an effect mediated by SFKs, Western blot
analysis showed a significant increase in phosphorylation of
p120-Y228 in cultures treated with TNF-a, and this was sig-
nificantly reduced by SU6656 (Fig 5, A and B). No tyrosine
phosphorylation of Y280 was detected, although the total
p120 antibody was positive at a similar level under all condi-
tions, confirming that the total amount did not change in re-
sponse to TNF-a (Fig 5, A).SU6656 enhanced epithelial barrier function in
low-resistance ALI cultures from patients with
severe asthma
In view of the barrier enhancement seen with SU6656 in the
context of TNF-a, we tested its effect on differentiated ALI
epithelial cultures from patients with severe asthma. These
cultures exhibited reduced barrier capacity, as previously de-
scribed in differentiated cultures from patients with severe
asthma.20 In these cultures, transepithelial permeability was
high compared with healthy cells, reading lower TER (median,
380 ohm/cm2; range, 8-1248 ohm/cm2) and increased FITC-
dextran permeability (median, 2.2; range, 1.0-16.0). SU6656 ef-
fected a trend for improvement in TER and a significant decrease
in macromolecular permeability (Fig 6, A and B). Consistent with
this effect, the low levels of junctional staining for occludin,
E-cadherin, and p120 in XZ stacks of control cells (Fig 6, C, E,
G, and I) was increased and showed stronger junctional localiza-
tion in the presence of SU6656 (Fig 6, D, F, H, and J).Immunostained human airway from patients with
severe asthma showed reduced E-cadherin and
p120 catenin
Severe asthma is an example of airway inflammation in which
TNF-a and neutrophil numbers are often increased37 and occlu-
din is reduced.20 In view of the effects of TNF-a on the AJ in cul-
tured HBECs, we sought to quantify whether E-cadherin and
p120 catenin were also affected in serial sections of bronchial bi-
opsies from patients with severe asthma. The asthmatic subjects
used (n5 6) all had a British Thoracic Society asthma score of 4/
5 and depended on corticosteroids, so they were likely to have
elevated TNF-a.37 In healthy controls (n 5 6), the distribution
of E-cadherin and p120 staining coincided at subapical junc-
tional areas and lateral cell borders, including proximity to the
upper surfaces of basal cell membranes (Fig 7, A and B, arrows).
Staining for E-cadherin and p120 also coincided where present in
FIG 6. Effect of SU6656 on barrier function and TJ staining in HBECs from severe asthma. A, Day 4 TER
(n 5 4). B, Day 4 FITC-dextran permeability (n 5 4). Representative immunofluorescent photomicrographs
(n 5 4) are controls (C, E, G, and I) or SU6656 (D, F, H, and J) for claudin-4 (C and D), occludin (E and F),
E-cadherin (G and H), and p120 (I and J) with TJ staining green and nucleii stained red. XZ stacks are
labeled apical and basolateral. Scale bar, 50 mm. Ap, Apical; Baso, basolateral; C, control; cl4, claudin-4;
occl, occludin; SU, SU6656.
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cantly reduced in the apical junction areas (Table I) and often
lost or faint in the lateral borders of suprabasal cells (Fig 7, D
and E, arrows). Staining for neutrophil elastase confirmed the
presence of neutrophils in the subepithelial regions of healthy
and asthmatic tissues (Fig 7, C and F, arrows), whereas asthmatic
tissue sections showed significant small numbers of neutrophils
within suprabasal epithelium (Fig 7, F, arrow).DISCUSSION
Recognizing that TNF-a expression is elevated in severe
asthma,21,22,37 we sought to gain further insight into its effects
on the bronchial epithelium. With the use of ALI cultures to
model differentiated epithelium, we found that TNF-a caused
an increase in both ionic and macromolecular permeability in as-
sociation with an increase in proinflammatory cytokine expres-
sion, reflecting the influence of the epithelium in innate
immunity. The changes in macromolecular barrier permeability
were linked to changes in integrity of both TJs and AJs, and
SFKs were found to play a role in these effects, both in response
to TNF-a and in cultures from patients with severe asthma. The
distribution of E-cadherin and p120 catenin in TNF-a–treated
ALI cultures reflected that of ex vivo bronchial biopsies from
the airways of patients with severe asthma, suggesting that barrier
disruption in vivo may contribute to innate immune responses.38Similar changes in ionic and macromolecular permeability in
response to TNF-a have been observed in healthy and cystic
fibrosis epithelia24 or in an epithelial coculture model with fibro-
blasts,25 whereby synergistic effects with IFN-g were observed.
In the present study, the altered barrier responses were associated
with striking effects of TNF-a on occludin and claudin-4, which
were highly reproducible and appeared to control different as-
pects of the barrier permeability. Changes in occludin expression
and localization are consistent with increased macromolecular
permeability, as shown previously in studies that used occludin
mutants.10 In contrast, claudin-4 expression has been shown to
decrease transepithelial permeability to sodium ions relative to
chloride39; therefore, its loss from TJs is consistent with the
TNF-a–mediated reduction in TER and corresponding increase
in paracellular ion permeability. Although a previous study that
examined the effect of a combination of TNF-a and IFN-g did
not find loss of either claudin-4 or occludin from the TJs in the
face of reduced barrier function,24 this may be due to the addi-
tional presence of IFN-g or that the antibody in the earlier study
only recognized the low molecular weight (ie, nonphosphory-
lated) form of occludin.
Our study showed increased proMMP-9 release in response to
TNF-a, consistent with other studies in HBECs.31,40 Although ex-
ogenous MMP-9 has been shown to degrade TJs,41 we could not
show a causal relationship between MMP-9 activity and barrier
disruption; indeed, we failed to detect MMP-9 activation by zy-
mography or with a highly sensitive fluorescent collagen IV
FIG 7. Localization of E-cadherin, p120, and neutrophil elastase. Representative photomicrographs of
healthy (n 5 4) (A-C) and severe asthmatic epithelium (n 5 4) (D-F) showing staining of glycolmethacrylate
serial sections of bronchial biopsies with E-cadherin (A and D), p120 catenin (B and E) and neutrophil elas-
tase (C and F). In patients with asthma, neutrophil elastase–positive cells were intraepithelial, and junctional
staining was often lost (insets and arrows indicate positive staining). Scale bar, 50 mm.
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of proMMPs,42 and claudin-2 knockdown decreased MMP-9 ac-
tivity in A549 cells.43 The possibility that MMP-9 might be acti-
vated at epithelial extracellular TJ contact points was tested with
exogenousMMP inhibitors, but these failed to prevent barrier dis-
ruption. In summary, although a second stimulus or cell type may
activate proMMP-9 in vivo, for example, during penetration of
dendritic cells into respiratory epithelium during inflammation,44
we could find no evidence ofMMP-9–mediated barrier disruption
in our bronchial model.
In the present study, we showed that E-cadherin and p120
catenin staining were relocated away from junctions after
treatment with TNF-a. Previous studies have shown loss ofE-cadherin in response to TNF-a in primary bronchial epithelial
cells and human nasal epithelial cells.45 Opening of TJs has been
shown to be affected by E-cadherin–containing AJs in MDCK I
monolayers, with function-blocking antibodies to E-cadherin re-
ducing the TER and perturbing TJ formation.15,17,46 In 16HBE
cells, down-regulation of E-cadherin with small interfering
RNA led to a decrease in epithelial impedance sensing, suggest-
ing a link between E-cadherin and barrier function.47 The changes
we observed in p120 localization are consistent with a stabilizing
role for E-cadherin in the AJ.48,49
The SFK inhibitor, SU6656,29 significantly inhibited TNF-
a–induced increase in macromolecular permeability, restored
occludin to the TJ complex, and blocked the increase in tyrosine
TABLE I. Analysis of immunohistochemical staining of
E-cadherin, p120 catenin, and neutrophil elastase in healthy
subjects compared with subjects with severe asthma
Subjects studied Healthy Severe asthma P value
No. subjects 6 6
E-cadherin AJ* 93 (73-99) 38.5 (7-60) <.01
E-cadherin lat memb 80 (6-94) 49 (16-72) .056
*p120 cat AJ 94 (72-97) 39 (9-65) <.01
p120 cat lat memb 81 (10-88) 47.5 (12-70) <.05
LP neutrophils (no. per mm2) 36.5 (13-147) 75.5 (23-396) .178
Neutrophils (no. per mm epi) 0 (0) 2.4 (0-3) <.01
Data are presented as median (range). P values of asthma versus healthy control.
AJ, Adherens junction; Epi, epithelium; lat memb, basolateral membrane; LP, lamina
propria; p120 cat, p120 catenin.
*Junctional staining was determined by observing 20 cells per 5 fields and expressed
as the number of positive cells.
Lateral membrane staining was determined as the percentage of membrane staining
in 20 cells per 5 fields.
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the inhibitor. The faster migrating, higher intensity band of
p120 pY228 most likely represents p120 isoform 3A, which is
the most common form in epithelial cells.50 These data suggest
one or more kinases from the src family are involved in mediating
aspects of TNF-a–induced barrier disruption, because SU6656
targets a number of SFKs, including src, fyn, fer, and c-yes, that
associate with p120 catenin35 and are activated with TNF-a.51
Consistent with this, TNF-a has been shown to induce phospho-
rylation of src in the airway epithelial cell line BEAS2B.32 The
association of p120 with cadherins may be affected by phospho-
rylation of other components of the cadherin complex, such as
b-catenin, Rho, or Rac, which have variable roles in regulating
assembly and disassembly of cell junctions.35,52 The Rac activa-
tor Tiam1 promotes assembly of AJs but has been shown to be
phosphorylated by src and degraded with AJ disassembly,53 sug-
gesting SFKsmay inhibit aspects of junction assembly in addition
to p120 Y228 phosphorylation. Occludin has been shown to be a
target of c-src, with tyrosine residues in conserved sites impli-
cated in protein interactions in TJ assembly.5
Importantly, it was possible to test the principle that the src-
type kinase inhibitor, SU6656, could enhance the barrier proper-
ties of low-resistance cultures from patients with severe asthma.
This showed that asthmatic cells responded favorably to SU6656
treatment with barrier enhancement and confirmed the need for a
larger more comprehensive study of samples from different
cohorts of asthmatic patients.
Addition of TNF-a to the ALI cultures upregulated endoge-
nous TNF-a release and caused significant increases in IL-6,
IL-1b, IL-8, and TSLP, in addition to effects on barrier control,
thus reflecting the pivotal role of the epithelium in innate
immunity. Elevated levels of IL-6 have been found in bronchial
lavage fluid and epithelia of patients with asthma.54,55 IL-6 was
also released from lung explants in response to TNF-a induction
by lipopolysaccharide56 and has been linked to airway fibrosis by
its ability to inhibit apoptosis.57 In colonic mucosa IL-6 disrupted
the barrier and increased pore-forming claudin-2,58 and in human
breast cancer cells IL-6 caused loss of E-cadherin.59 However, in
our model a neutralizing antibody against IL-6 had no effect on
the TNF-a–mediated changes in barrier permeability or TJ pro-
teins. TNF-a also caused a large increase in IL-1b release after
24 hours. IL-1b has previously been shown to affect airwayepithelial TER24; however, an IL-1b–neutralizing antibody did
not alter the TNF-a–induced permeability changes. Consistent
with these negative results of cytokine neutralization on epithelial
permeability, we failed to show significant inhibition of IL-6 or
IL-1b release by SU6656, attesting to distinct regulatory path-
ways. Similar to other studies, TNF-a treatment led to a sig-
nificant increase in IL-8 release60 and TSLP.61 In contrast with
IL-6 and IL-1b, TSLP has been reported to enhance tight-
junction barrier function by upregulating the expression of occlu-
din and claudin-1, -4, and -7 in human nasal epithelial cells when
cocultured with dendritic cells, and it has been proposed that this
may regulate antigen sensitization.44 However, in our experi-
ments, the presence of TSLP did not overcome the barrier-
disrupting effects of TNF-a, and SU6656 did not affect TSLP
expression.
The SU6656 inhibitor also caused significant reductions in
endogenous TNF-a release. This may be linked to restoration of
E-cadherin and p120 because loss of E-cadherin and p120 were
reported to activate nuclear factor k B and increase expression of
TNF-a, IL-6, and IL-1b by airway epithelial cells.19 In view of
the effect of TNF-a on E-cadherin and p120 distribution in differ-
entiated HBECs, we investigated the expression of E-cadherin
and p120 in inflamed airway. We found that membrane junctional
localization of E-cadherin and p120 catenin was reduced or lost in
bronchial biopsies from severe neutrophilic asthma, which resem-
bled the alterations in staining distribution that we detected in our
differentiated HBECs treated with TNF-a and junctional loss
seen in cultures from severe asthmatic donors. Further work is re-
quired to study the extent of this change in human airway disease,
although loss of E-cadherin has previously been reported in atopic
asthma.18
In summary, TNF-a–mediated loss of airway epithelial barrier
function, correlating with disruption or loss of TJs and AJs, was
susceptible to modification by the SFK inhibitor SU6656, which
affected the macromolecular permeability rather than the ionic
permeability, attesting to the complexity and subtly of TJ barrier
regulation. The release of TNF-awas also influenced by SU6656,
suggesting that topical airway targeting of kinase pathways, that
simultaneously affect barrier and cytokine responses, may pro-
vide a fruitful therapeutic approach in future.
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copy and preparation of figures; Dr Susan Wilson and Mr John Ward,
Histochemistry ResearchUnit, SouthamptonGeneral Hospital; and the staff in
the National Institute for Health Research Respiratory Biomedical Research
Unit in Southampton, which enabled the bronchoscopic sample collection.
Volunteer recruitment was facilitated by the MRC-funded Wessex severe
asthma cohort.
Clinical implications: These studies suggest that targeting air-
way barrier defects in asthma with src family kinase inhibitors
presents a potential therapeutic approach for patients whose
disease is refractory to conventional therapies.REFERENCES
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Clinical characterization of subjects and
bronchoscopy
After ethical approval and written informed consent, subjects were clinically
characterized and then underwent fiberoptic bronchoscopy under local anesthe-
siaE1 for collection of bronchial biopsies and brushings. All volunteers were non-
smokers and had been free from respiratory tract infections for at least 4 weeks
before the study. Further human subject information is contained in Table E1.
Culture and differentiation of primary BECs
BECs were grown from bronchial brushingsE2 in bronchial epithelial
growth medium (Lonza, Slough, United Kingdom) and cultured on 24-well
Transwell inserts (Corning Costar, Corning, NY). Differentiation at an
ALI was induced after a modification of Gray et al.E3 After 21days, diff-
erentiated cultures were starved for 24 hours in bronchial epithelial basal
medium (Lonza) with insulin, transferring and sodium selenite (13ITS;
Sigma-Aldrich) and then treated basolaterally with TNF-a (10 ng/mL) and
basolaterally or apically with other mediators and inhibitors in starvation
medium as outlined in the Methods section. Cell-conditioned basolateral
media supernatant fluids were stored at 2808C before further assay. For
each experiment, data were derived from between 3 and 6 Transwells per
condition, and experiments were repeated a minimum of 3 times.
Measurement of TER
The TER was measured in confluent cells on 0.3-cm2 filters with the use of
an EVOM voltmeter and a STX2 electrode (World Precision Instruments), in
starvation medium with 100 mL added to the apical compartment. The cells
were incubated at 378C for 20 minutes before taking readings, followed by re-
moval of apical medium to return the cells to an ALI. Experimental readings
had background readings from an insert containing mediumwithout cells sub-
tracted from them and were expressed per centimeter-squared filter as fold
change compared with control.
Assessment of epithelial barrier integrity
The passage of uncharged molecules across confluent cells on 0.3-cm2 filter
inserts was measured with a fluorescein isothiocyanate (FITC)-conjugated
4-kDa dextran (Sigma-Aldrich). Basolateral experimental medium (900 mL)
and250mLof apical 2mg/mLFITC-dextranmediumwere incubated for 3 hours
at 378C.Triplicate basolateralmedia samples were taken for assaying on an opa-
que 96-well Nunc plate (Fisher Scientific UK Ltd). A standard curve of FITC-
dextran inmedium(2 to0.03125mg/mL)was also run induplicate.Fluorescence
wasmeasured onafluorimeter at excitation and emissionwavelengths of 485nm
and 530 nm, respectively. The basolateral measurements were corrected for di-
lution factor by dividing the volume of the basolateral medium by the volume of
the apical medium and multiplying the readings by this number.
Exogenous cytokines, small molecule inhibitors,
and neutralizing antibodies
The TNF-a cytokine (R&D Systems Europe Ltd) was reconstituted in PBS
containing 0.1% BSA, and the stock solutions were stored at 2208C. The
src family kinase inhibitor SU6656E4 (Sigma-Aldrich), MMP-9 inhibitor
1 (Merck), and GM6001 (Millipore) were reconstituted in dimethyl sulfoxide.
Cells were preincubated with inhibitors for 2 hours before adding TNF-a.
GM6001 MMP inhibitor
GM6001 is a broad-spectrum hydroxamate inhibitor of matrix metal-
loproteinases (MMPs). It inhibits human MMPs with the following Ki values:
MMP-1, 0.4 nmol/L; MMP-2, 0.5 nmol/L; MMP-3, 27 nmol/L; MMP-7, 3.7
nmol/L; MMP-8, 0.1 nmol/L; MMP-9, 0.2 nmol/L; MMP-12, 3.6 nmol/L;
MMP-14, 13.4 nmol/L; MMP-26, 0.36 nmol/L.E7-E9
Immunocytochemistry
The cell monolayers grown on filter inserts were fixed in 50:50 acetone/
methanol at 2208C for 20 minutes before washing with PBS (Invitrogen).After the being cut from the insert wells and transferred tomicroscope slides in
a humidified chamber, the membranes were blocked with PBS containing 5%
goat serum (Vector Laboratories) and 1% BSA (Sigma-Aldrich) for 30
minutes, then incubated with primary antibody for 2 hours at room temper-
ature in PBS with 1% BSA: mouse anti–claudin-3, mouse anti–claudin-4,
rabbit anti–claudin-8, mouse anti-occludin, mouse anti–E-cadherin (all
Invitrogen) and mouse anti-p120 catenin (BD Biosciences). Nonimmune
mouse immunoglobulin (Serotec Ltd, Oxford, United Kingdom)was used as a
negative control. After PBS washes, the filters were incubated with secondary
antibody for 1 hour at room temperature in the dark: Alexa Flour 488–goat–
anti-mouse (Invitrogen). All antibody dilutions weremadewith PBS 1%BSA.
After further washes, a cell nuclear counterstain, 7-amino-actinomycin D was
incubated for 10 minutes at room temperature in the dark, followed by further
PBS washes. The filters were then mounted with Mowiol mountant
(Calbiochem, Nottingham, United Kingdom). The slides were viewed on a
laser confocal scanning microscope (Leica SP5) with identical settings
between control and experimental filters. ZX stacks and overlays were made
with the Leica Lite imaging software.
Immunohistochemistry
Bronchial biopsies embedded and sectioned in glycolmethacrylate resin
were immunostained with mAbs against E-cadherin (Invitrogen), p120
catenin (BD Biosciences), and neutrophil elastase (clone NP57; Dako) with
the use of standard protocols.E5 In all cases, analyses were restricted to areas of
well-orientated and structurally intact epithelium. All slides were randomly
coded and assessed by an observer blinded to the code. Junctional staining
was determined by observing 20 cells per 5 fields and expressed as the number
of positive cells; lateral membrane staining was determined as the percentage
of membrane staining in 20 cells per 5 fields, and neutrophils present in the
bronchial epithelium or lamina propria were counted and quantified as previ-
ously described.E6
Western blot analysis
Cells were lysed in SDS buffer (0.5 mmol/LTris, 10% SDS, 1 mol/L DTT,
glycerol, protease inhibitors, phosphatase inhibitors), and the protein con-
centration was determined with a biocinchoninic acid (Perbio Science Ltd,
Cramlington, United Kingdom) assay. Proteins (16 mg) were run on Bio-Rad
precast gels (Bio-Rad, Hercules, Calif) before being transferred onto
polyvinylidene difluoride membranes (Amersham Biosciences, Buckingham-
shire, United Kingdom) for Western blot analysis. Benchmark prestained
protein ladders (Invitrogen) consisting of proteins of known molecular
weights (10-190 kDa) were also run. The membrane was blocked for 1 hour
in ECL blocking solution (Amersham Biosciences) before being incubated
with primary antibodies in blocking solution overnight at room temperature:
mouse anti-p120 catenin (Y228) andmouse anti-total p120 catenin (both from
BD Transduction Laboratories). After washing with TBS 0.1% Tween 20
(Sigma-Aldrich) themembranewas incubated for 3 hours at room temperature
with secondary antibody: ECL–anti-mouse IgG HRP-linked antibody or
ECL–anti-rabbit IgG HRP-linked antibody (Amersham Biosciences). After
further washes, the blots were developed with the ECL Advance kit
(Amersham Biosciences), and the resulting chemiluminescence signal was
detected with the Versadoc imaging system (Bio-Rad) at a wavelength of 430
nm. Blots were probed with rabbit anti–b-actin (Abcam, Cambridge, United
Kingdom) as a loading control. Membranes were stripped by incubating in a
solution of 2% wt/vol SDS, 62.5 mmol/L Tris HCl, 100 mmol/L 2-
mercaptoethanol (pH 6.7; Sigma-Aldrich) for 30 minutes at 558C. Blots
were analyzed with the Quantity one software (Bio-Rad).
MSD multiplex cytokine array
Conditionedmedia from primaryHBECs treated with TNF-awere assayed
for IL-1b, IL-6, IL-8, TNF-a, IL-10, and MMP-9 with the use of a
commercially available electrochemiluminescence immunoassay according
to the manufacture’s protocol (Meso Scale Discovery, Rockville, Md). This
assay uses a sandwich immunoassay format in which captured antibodies are
precoated onto the bottom of each well in a single spot (IL-10 and MMP-9) or
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HARDYMAN ET AL 675.e24-spotmultispot (IL-1b/IL-6/IL-8/TNF-a) format on themicroplate provided.
Briefly, 25 mL of appropriately diluted calibrator, control, or sample were
loaded in duplicate and incubated for 1.5 hours on a shaker at room
temperature. In the case of the MMP-9 assay the plate was washed with
PBS/ 0.05% Tween-20. Next, 25 mL of cytokine-specific detection antibody
labeled with a SULFO-TAGwas added and incubated at room temperature for
1.5 hours on a shaker. After washing, 100 mL of read buffer was added to each
well, and the plate was read on an MSD SECTOR imager (Meso Scale
Discovery). If the sample contains the cytokine of interest, the bound SULFO-
TAG labels come into close proximity to the bottom of the well and emit light
on electrochemical stimulation initiated at the electrode surfaces of the
multispot microplates. The output signal is in units of counts of light and is
proportionate to the amount of bound cytokine. The MSD software then uses
the calibration curve generated to calculate the levels of cytokine present in
each sample.
ELISAs
Conditionedmedia from primaryHBECs treated with TNF-awere assayed
for TSLP, TIMP-1, or IL-33 with the use of a commercially available ELISA
according to the manufacturer’s protocol (R&D Systems). This assay uses the
quantitative sandwich enzyme immunoassay technique. Briefly, 100 mL of
assay diluent was added to each well of a 96-well microplate precoated with a
polycolonal antibody specific for the protein of interest. Next, 50 mL of
appropriately diluted standards, controls, and experimental samples were
loaded in duplicate and incubated for 2 hours. After washing, 200 mL of
polyclonal antibody conjugated to HRP was incubated for 2 hours. After
further washes, 200 mL of tetramethylbenzidine HRP substrate solution was
added and incubated for 30 minutes protected from light. The resulting
enzyme reaction produced a blue product, which turned yellowwhen 50mL of
2 mol/L sulfuric acid stop solution was added. The color intensity was
measured at 450 nm with a 540-nm reference filter with the use of a Dynatech
MR7000 plate reader. The color change seen is proportionate to the amount of
specific protein bound in the initial step. A blank value from wells containing
assay buffer only was analyzed and subtracted from each value. The specific
protein content from each well was then estimated by direct reading from a
plotted standard curve.
Zymography assay
Novex zymogram gelatin gels (Invitrogen) were used to look at the
expression and activity of epithelial released MMPs. The basolateral media
supernatant fluid was taken every 24 hours from HBECs grown at ALI
incubated with or without TNF-a (10 ng/mL). Active MMP-9 and MMP-2
were used as positive controls, and media not previously exposed to cells
were run as a negative control. These were denatured in Novex Tris-glycine
SDS sample buffer (23) (Invitrogen), then electrophoresed on a zymogram
gel (10% Tris-glycine gel with 0.1% gelatin incorporated as a substrate)
with the use of a 13 Tris-Glycine SDS running buffer (Invitrogen) at 125 V
for 90 minutes. The gel was then incubated in 13 Novex zymogram
renaturing buffer containing a nonionic detergent (2.5% vol/vol Triton X-
100; Invitrogen) for 30 minutes at room temperature with gentle agitation to
re-nature any MMP enzyme present, then equilibrated in zymogram
developing buffer (Invitrogen) overnight at room temperature with gentle
agitation to add the divalent metal cation required for enzymic activity,
before being washed in water to remove any buffer and stained with
Coomassie blue 10 minute at room temperature. The gel was then washed 3
times with water before being put in de-stain. Any protease activity present
is visualized as a clear band in which the protease has digested the
substrate. The gel was photographed on the Versadoc imaging system
(BioRad).
DQ Collagenase activity assay
To test the enzymic activity ofMMP-9 an EnzCheck collagenase assay was
run (Invitrogen [Molecular Probes]). Media supernatant fluids were taken
every 24 hours from the basolateral chamber of ALI cultures incubatedwith or
without TNF (10 ng/mL). A known substrate for MMP-9 (100 mg/mL),collagen type IV (Invitrogen), so heavily conjugated to fluorescein that the
fluorescence was quenched, was loaded onto a black 96-well plate along with
80 mL of a reaction buffer provided with the kit and 100 mL of basolateral
media supernatant fluid in duplicate. Reaction buffer alone and media not
previously exposed to cells were run in duplicate to act as negative controls,
and 100mL of Clostridium collagenase (0.05U/mL), in duplicate, was run as a
positive control. The platewas briefly put on a plate shaker tomix before being
incubated for 18 hours away from light, then the fluorescence was read on a
SpectraMax plate reader at 495 nm, with a reference filter of 515 nm. If active
MMPs are present, the collagen is cleaved and fluorescence is released. The
fluorescence seen is therefore proportional to proteolytic activity present.
A blank value, derived from an average of the readings measured from wells
containing reaction buffer and media alone, was subtracted from each
experimental value.
LDH assay
To quantitate any cytotoxic effects of TNF-a, a LDH cytotoxicity detection
assay was performed on the conditioned media from primary HBECs
according to the manufacturer’s protocol (Roche Diagnostics Ltd, Burgess
Hill, United Kingdom). Briefly, 100 mL of cell-free supernatant fluid was
loaded on to an optically clear flat bottommicroplate in duplicate. Media from
cells treated with 1% Triton-X 100 for 30 minutes were used as a positive
control, and media not previously exposed to cells were used as a negative
control. This was incubated protected from light at room temperature for 30
minutes with 100 mL of a reaction mixture containing a catalyst mixture
(Diaphorase/NAD1) and dye Solution (INT and sodium lactate). LDH
activity was determined by a coupled enzymatic reaction during which the
tetrazolium salt INT was reduced to formazan. This was then assayed on a
Dynatech MR7000 plate reader at 490 nm with a reference wavelength of 630
nm. The amount of formazan produced is proportional to LDH activity. After
subtracting the blank, the experimental readings were expressed as a
percentage of Triton-X–positive control.
Statistics
Data were evaluated with nonparametric Wilcoxon rank sum or 2-way
ANOVA test. All the data were analyzed with Prism (GraphPad Software, La
Jolla, Calif).
FIG E1. Effect of TNF-a on HBECs showing dose (A-C) and time (A and D)
responses for changes in TER (A and B), and FITC dextran permeability (C
and D). E, Shown is LDH release over time in response to 10 ng/mL TNF-
a compared with controls.
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FIG E2. Western blot analysis in upper panel shows HBECs treated for 4
days with TNF-a, compared with untreated controls and stained for
claudin-3, -4, -8, and occludin. No consistent or significant differences in
expression levels were observed, as seen from the quantitation of band
density shown in lower panel (n 5 3).
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FIG E3. TNF-a did not promote the release of IL-10 or IL-33 from differen-
tiated HBECs. Basolateral medium, taken every 24 hours from cells treated
with 10 ng/mL TNF-a, was assayed by ELISA for IL-10 (A) or IL-33 (B) and
showed no significant change in either cytokine (n 5 4).
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FIG E4. TNF-a (shaded bars) caused an increased release of proMMP-9 from primary airway epithelial cells,
whereas TIMP-1 expression was unaffected. Basolateral medium was assayed every 24 hours from cells
treated with 10 ng/mL TNF-a. A, Zymography (n 5 4) showed the presence of proMMP-9; no other type
of MMP was detected on the gels. B,MSD MMP-9 array (n 5 4) showed that TNF-a caused a significant in-
crease in proMMP-9 release after 24 hours compared with controls. MMP-9 release increased further for 3
days, although these later time points were not statistically different from controls because of the range of
responses. C, Low proteolytic activity was detected in the basolateral media from control HBECs, but this
was not significantly different from TNF-a treatment, confirming that most proMMP-9 was not activated
(n 5 4). D, The levels of TIMP-1 in the basolateral media of control and TNF-a–treated HBECs was deter-
mined by ELISA and was not significantly different from controls over time (n 5 4).
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FIG E5. TheeffectofSU6656ontheTNF-a–mediatedTERandcytokineeffects
in primary HBECs.A, Shown is the TER over time with no significant effect at
day 4 (n5 8) (see Fig 3,A for P values). Concentration of innate immune cyto-
kines into the basolateralmediawas assayedevery 24hours and subjected to
MSDassay for IL-1b (B), IL-6 (C), and IL-8 (D). TheSU6656 inhibitor hadno sig-
nificant effect on the release of cytokines in the presence of 10 ng/mL exoge-
nous TNF-a. Controls, light shaded bars; TNF-alpha, dark shaded bars.
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TABLE E1. Subject details presented for the whole study group and for each separate study group
Subjects No. Sex (M/F)
Age (y),
mean (range)
FEV1 (% predicted),
mean (SEM) BTS
ICS dose (mg/d),
mean (SEM)
Biopsies for immunohistochemistry
Healthy 6 4/2 26 (20-36) 102.5 (3.96) 0 0
Severe asthma 6 3/3 49.5 (42-61) 75.2 (4.41) 4/5 2500 (428.2)
Differentiated ALI cultures
TNF response 9 1/9 40.3 (20-65) 107.4 (4.19) 0 0
TNF MMP-9 8 0/9 36.4 (19-65) 105.8 (6.37) 0 0
TNF SU6656 8 3/5 43.4 (19-72) 103.7 (9.57) 0 0
Severe asthma SU6656 4 1/3 42.3 (24-53) 76 (12.9) 4/5 2462.5 (405.3)
BTS, British Thoracic Society asthma guideline; F, female; ICS, inhaled corticosteroid; M, male.
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